Sevelda F, Waldstein W, Panotopoulos J, Stihsen C, Kaider A, Funovics P T, Windhager R
Department of Orthopaedics, Medical University of Vienna, Austria.
Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Austria.
Eur J Surg Oncol. 2017 Feb;43(2):416-422. doi: 10.1016/j.ejso.2016.11.005. Epub 2016 Nov 23.
Tumor spread to the knee joint or skip metastasis to the adjacent bones of the knee require reconstruction with combined distal femur and proximal tibia replacements. The literature on implant survival and failure modes with this type of reconstruction is sparse. The goals of this study were to determine the implant survival, the different failure modes and the functional outcome of this megaendoprosthetic reconstruction.
Thirty-nine patients with combined distal femur and proximal tibia reconstruction were retrospectively reviewed. Median follow-up was 8.8 years (quartiles 4.7-15.5 years). Twenty-one patients received combined distal femur and proximal tibia reconstruction as a primary mode of reconstruction, 18 patients as revision surgery after failed tumor prosthesis. For survival estimations, competing risk analyses were performed.
The revision-free survival at five years was 42% (95% CI 22%-56%) and implant survival with exchange of the original implant was 54% (95% CI 35%-68%). Five-year revision-free survival for soft tissue failure was 72% (95% CI 52%-84%), for infection 67% (95% CI 48%-80%), for structural failure 82% (95% CI 63%-91%), for aseptic loosening and tumor progression 97% (95% CI 82%-99%), respectively. Patients with revision surgery had higher risk for infection (p < 0.001), structural failure (p = 0.037) and shorter revision-free- (p = 0.025) and implant-survival (p = 0.006). Limb survival at 20 years was 94%. Mean musculoskeletal Tumor Society score was 76%.
Despite high failure rates with short revision-free survivals, combined distal femur and proximal tibia reconstruction achieved longtime limb survival in the majority of patients with satisfying function.
肿瘤扩散至膝关节或跳跃转移至膝关节相邻骨骼时,需要采用远端股骨和近端胫骨联合置换进行重建。关于此类重建的植入物生存率及失败模式的文献较少。本研究的目的是确定这种大型内置假体重建的植入物生存率、不同的失败模式及功能结果。
对39例行远端股骨和近端胫骨联合重建的患者进行回顾性研究。中位随访时间为8.8年(四分位数间距4.7 - 15.5年)。21例患者接受远端股骨和近端胫骨联合重建作为初次重建方式,18例患者在肿瘤假体失败后接受翻修手术。采用竞争风险分析进行生存估计。
五年无翻修生存率为42%(95%可信区间22% - 56%),通过更换原植入物的植入物生存率为54%(95%可信区间35% - 68%)。软组织失败的五年无翻修生存率为72%(95%可信区间52% - 84%),感染为67%(95%可信区间48% - 80%),结构失败为82%(95%可信区间63% - 91%),无菌性松动和肿瘤进展为97%(95%可信区间82% - 99%)。接受翻修手术的患者感染风险更高(p < 0.001),结构失败风险更高(p = 0.037),无翻修生存期更短(p = 0.025),植入物生存期更短(p = 0.006)。20年肢体生存率为94%。肌肉骨骼肿瘤学会平均评分为76分。
尽管失败率高且无翻修生存期短,但远端股骨和近端胫骨联合重建在大多数患者中实现了长期肢体存活,且功能满意。